JAK1 and rheumatoid arthritis: A clinical study comparing the periodontal status of patients with periodontitis and rheumatoid arthritis at baseline and 24 weeks after oral treatment with a JAK1-3 inhibitor indicated a reduction in periodontal inflammation [54].